230 related articles for article (PubMed ID: 33147331)
21. Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma?
Knösel T; Werner M; Jung A; Kirchner T; Dürr HR
Pathol Res Pract; 2014 Mar; 210(3):194-7. PubMed ID: 24405942
[TBL] [Abstract][Full Text] [Related]
22. CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Ramsey DC
Clin Orthop Relat Res; 2024 Jun; 482(6):957-959. PubMed ID: 38446419
[No Abstract] [Full Text] [Related]
23. Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Zhang Y; Paz Mejia A; Temple HT; Trent J; Rosenberg AE
Hum Pathol; 2014 Jul; 45(7):1541-5. PubMed ID: 24792622
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
25. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma.
Zhang Y; Chen Y; Yang C; Seger N; Hesla AC; Tsagkozis P; Larsson O; Lin Y; Haglund F
Mod Pathol; 2021 Nov; 34(11):2020-2027. PubMed ID: 34108637
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1.
Oyama R; Kito F; Takahashi M; Sakumoto M; Shiozawa K; Qiao Z; Noguchi R; Kubo T; Toki S; Nakatani F; Yoshida A; Kawai A; Kondo T
Hum Cell; 2019 Apr; 32(2):202-213. PubMed ID: 30737713
[TBL] [Abstract][Full Text] [Related]
29. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
[TBL] [Abstract][Full Text] [Related]
30. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
31. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
32. Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.
Hung YP; Diaz-Perez JA; Cote GM; Wejde J; Schwab JH; Nardi V; Chebib IA; Deshpande V; Selig MK; Bredella MA; Rosenberg AE; Nielsen GP
Am J Surg Pathol; 2020 Sep; 44(9):1213-1223. PubMed ID: 32427623
[TBL] [Abstract][Full Text] [Related]
33. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
[TBL] [Abstract][Full Text] [Related]
34. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis.
Bovée JV; Cleton-Jansen AM; Rosenberg C; Taminiau AH; Cornelisse CJ; Hogendoorn PC
J Pathol; 1999 Dec; 189(4):454-62. PubMed ID: 10629543
[TBL] [Abstract][Full Text] [Related]
36. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
van Oosterwijk JG; de Jong D; van Ruler MA; Hogendoorn PC; Dijkstra PD; van Rijswijk CS; Machado I; Llombart-Bosch A; Szuhai K; Bovée JV
BMC Cancer; 2012 Aug; 12():375. PubMed ID: 22928481
[TBL] [Abstract][Full Text] [Related]
37. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality.
Lin Y; Seger N; Chen Y; Hesla AC; Wejde J; Ghaderi M; Tsagkozis P; Larsson O; Haglund F
Mod Pathol; 2018 Dec; 31(12):1834-1841. PubMed ID: 30065261
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of miRNA expression in dedifferentiated and well-differentiated components of dedifferentiated chondrosarcoma.
Karras FS; Schreier J; Körber-Ferl K; Ullmann SR; Franke S; Roessner A; Jechorek D
Pathol Res Pract; 2023 Apr; 244():154414. PubMed ID: 36963273
[TBL] [Abstract][Full Text] [Related]
39. IDH-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
